<DOC>
	<DOCNO>NCT01834209</DOCNO>
	<brief_summary>The purpose study collect additional safety data treatment abiraterone acetate plus prednisone prednisolone among adult participant asymptomatic mildly symptomatic metastatic castration-resistant prostate cancer ( mCRPC ) reside area abiraterone acetate yet available indication local healthcare provider , eligible enrollment available ongoing clinical study abiraterone acetate .</brief_summary>
	<brief_title>A Study Abiraterone Acetate Plus Prednisone Asymptomatic Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description>This open-label ( identity assign study drug know ) early access protocol ( EAP ) . Approximately 60 participant enrol study . Participants receive abiraterone acetate 1000 mg daily plus prednisone prednisolone 5 mg daily . Treatment 28-day cycle continue progression clinical disease . Study drug provide company obtain market authorization reimbursement participant country indication .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell histology Not receive cytotoxic chemotherapy regimens metastatic castrationresistant prostate cancer Have prostate cancer progression assess investigator prostatespecific antigen progression accord Prostate Cancer Working Group 2 criterion Have asymptomatic mildly symptomatic prostate cancer Have ongoing androgen deprivation serum testosterone &lt; 50 ng/dL ( &lt; 2.0 nM ) Have Eastern Cooperative Oncology Group performance status &lt; =2 Laboratory value within protocoldefined parameter Adequate liver function accord protocoldefined parameter Be able swallow study drug whole tablet Agrees protocoldefined use effective contraception Eligible another study abiraterone acetate open enrollment Has receive abiraterone acetate past enrol Studies COUAA301 COUAA302 Has serious uncontrolled coexistent nonmalignant disease , include active uncontrolled infection Has uncontrolled hypertension ( systolic blood pressure &gt; =160 mmHg diastolic blood pressure &gt; =95 mmHg ) ; individual history hypertension allow provide blood pressure control antihypertensive therapy Has active symptomatic viral hepatitis chronic liver disease Has history pituitary adrenal dysfunction Has clinically significant heart disease evidence myocardial infarction , arterial thrombotic event past 6 month , severe unstable angina , New York Heart Association Class III IV heart disease leave ventricular ejection fraction &lt; 50 % baseline Has atrial fibrillation cardiac arrhythmia Has know brain metastasis Has prior cytotoxic chemotherapy biologic therapy treatment castrationresistant prostate cancer ( CRPC ) Has prior cytotoxic chemotherapy biologic therapy treatment CRPC Has active infection medical condition would make prednisone/prednisolone use contraindicate Has anticancer therapy include cytotoxic , radionucleotide , immunotherapy Has prior systemic treatment azole drug ; diethylstilbestrol ; PCSPES ; spironolactone ; preparation saw palmetto thought endocrine effect prostate cancer , within 4 week Cycle 1 Day 1 Is currently enrol investigational drug device study participate study within 30 day Day 1 Has condition situation , investigator 's opinion , may put participant significant risk , may confound study result , may interfere significantly participant 's participation study Has partner childbearing potential willing use method birth control adequate barrier protection determine acceptable principal investigator sponsor study 13 week last study drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Prostate neoplasm</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Metastatic prostate cancer</keyword>
	<keyword>Metatatic castration resistant prostate cancer</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Prednisolone</keyword>
	<keyword>Early access program</keyword>
</DOC>